SASreelatha Akkala

Sreelatha Akkala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sreelatha Akkala has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence, Trends, and Racial/Ethnic Disparities in Female Breast Cancer in the United States, 2000-2023: A SEER Based Study

    by Nompumelelo O. Mzizi, Sandile S. Ndabezitha, Julie A. Atta, Mohammad A. Al Zoubi, Sreelatha Akkala

    Introduction: In 2026, an estimated 321,910 new cases of invasive breast cancer will be diagnosed.However, there is a lack of comprehensive data on breast cancer incidence trends and how they vary across different age groups and racial and ethnic populations. Existing studies have evaluated breast cancer incidence trends over short periods, resulting in a lack of clear information on specific population variations over extended periods to ascertain disease-specific trends. Methods: We used the 2000-2023 Surveillance, Epidemiology, and End Results program dataset to analyze routine data and published cancer cases to identify incidence trends and disease burden by age and race/ethnicity using Joinpoint regression. We included new cases of breast cancer identified using International Classification of Diseases (ICD) codes. Patient’s demographic information was obtained from the medical records. Results: The overall breast cancer incidence among women was 190.8 per 100,000, showing an increasing trend from 2000 to 2023. There was also a significant increase in age-adjusted incidence rates in breast cancer trends from 2000 to 2023 (AAPC = 0.76%), with the highest incidence being reported in women aged 75–⁠79 years (456.3 per 100,000). Non-Hispanic white women recorded the highest incidence over the period (228.9 per 100,000). Non-Hispanic White women experienced increasing incidence trends between 2000 and 2023 (AAPC = 0.76%). Conclusion: From 2000 to 2023, there was a significant increase in breast cancer incidence trends in all groups, with notable rates among women in their 40s and above. These trends underscore the need for adaptive screening strategies and policy recommendations to initiate mammography at age 40. Progress could also be accelerated by understanding the associations among ethnic, racial, and other existing social disparities to ensure early diagnosis and treatment.


  • “Not in my backyard”: The impact of recovery residences on property values

    by Ryan Ramphul, Sheryl A. McCurdy, Jooyeon Lee, Yanchen Liu, Yixiao Chen, Serena A. Rodriguez, Kathryn R. Gallardo, Sreelatha Akkala, Hadiza Theyra-Enias, J. Michael Wilkerson


  • Open Access

    Socioeconomic Status and Breast Cancer Treatment in the United States: Results From a Systematic Literature Review

    by Sreelatha Akkala, Mohammed Zuber, Julie Alaere Atta, Nompumelelo O. Mzizi, Jyothi Akkula

    Background: In 2024, breast cancer is the second most common cancer globally, affecting 2.3 million women. In the United States (US), 310 720 new female breast cancer cases were estimated in 2024. Existing research has identified substantial disparities in breast cancer treatment and survival based on socioeconomic status (SES). This systematic review examines the association between the key SES indicators income, education, and occupation on breast cancer outcomes among the US breast cancer patients. Methods: An electronic search was conducted using Medline®, Embase®, and Web of Science, from inception to December 2023. Observational studies examining the influence of SES indicators on breast cancer outcomes, including treatment receipt, adherence, and survival, were included. Data were summarized qualitatively due to heterogeneity in SES measures and outcome definitions. Results: Of 2600 studies retrieved from the searches, 23 studies met the inclusion criteria (19 cohort, 4 cross-sectional). Women with lower SES were less likely to receive or experience delay in receiving the recommended treatment than women with higher SES. In addition, women with low household income (<$25,000) were more likely to report discontinuations in therapy as compared to women with an income of $50,000 or more. Education level influenced treatment adherence and timely care, with higher educational attainment linked to improved survival rates. Occupational status impacted treatment continuity, with low-wage jobs and inflexible work schedules contributing to delays and discontinuation of care. Conclusion: SES significantly influences breast cancer care and survival, with lower SES associated with delayed treatment, poorer adherence, and worse outcomes. Healthcare interventions and policies focusing on equitable access to quality care tailored to all women, regardless of their socioeconomic background, may improve breast cancer outcomes for the patients with various demographic characteristics in the US.


  • Open Access

    Efficacy and Effectiveness Outcomes of Treatments for Double‐Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review

    by Mohammed Zuber, Sreelatha Akkala, Niying Li, Sajesh K. Veettil, Chia Jie Tan, Lorenzo Villa Zapata

    Background: Bruton's tyrosine kinase inhibitors (BTKi) and the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL). BTKi/venetoclax‐treated patients with exposure to both novel agents (regardless of the reason for discontinuation) are classified as “double‐exposed,” and often have poor prognoses. This study aims to assess the efficacy and effectiveness of treatments in double‐exposed CLL patients.Methods: PubMed, Embase, and Web of Science databases were searched until December 2023.Results: We retrieved 3948 articles for screening and included 13 publications covering nine distinct studies. Three clinical trials reported a median PFS of 16.8 months with pirtobrutinib, 13 months with lisocabtagene maraleucel, and 10.1 months with nemtabrutnib. ORR ranged from 58% with nemtabrutinib and 80% with lisocabtagene maraleucel. In observational studies, PFS ranged from 3 months with chemoimmunotherapy to 12 months with BTKi, and ORR ranged from 31.8% with chemoimmunotherapy to 85.7% with chimeric antigen receptors (CAR) T‐cell therapy.Conclusion: This study highlights the limited clinical data on efficacy outcomes for double‐exposed CLL/SLL patients. Pirtobrutinib, lisocabtagene maraleucel, and a combination of ibrutinib and venetoclax have shown promising effects. However, the scarcity of treatment options and efficacy data for patients who have failed BTKi and venetoclax underscores a significant unmet medical need.